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Correlation between basic fibroblast growth factor
immunostaining of stromal cells and stromelysin-3
mRNA expression in human breast carcinoma
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Summary We examined the localization of basic fibroblast growth factor (bFGF) in a series of human breast carcinomas using
immunohistochemistry. Staining was observed in tumour cells in 15 out of 54 (28%) tumours and in the adjacent stroma in 34 out of 54 (63%)
tumours examined. No correlation was observed between positive staining of these two compartments. The relationship between bFGF
staining and expression of the metalloprotease stromelysin-3, and between bFGF and microvessel density, was examined. A statistically
significant correlation (P < 0.003) was observed between bFGF staining of the stromal compartment and high expression of stromelysin-3
(ST-3; MMP-1 1) metalloprotease mRNA by stromal cells. In contrast, no correlation was observed between bFGF and intratumour
microvessel density (IMD). These results raise the possibility that bFGF may be involved in the induction of stromelysin-3 mRNA expression
in breast cancer stroma.
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Basic fibroblast growth factor (bFGF) is encoded by a single-copy
gene that encodes several isoforms ranging from 18 to 24 kDa
(Basilico and Moscatelli, 1992). Tumour cell lines frequently
express bFGF. bFGF is believed to be important forthegrowth and
for the neovascularization of solid tumours (Folkman and Shing,
1992). Furthermore, bFGF can be demonstrated in neoplastic cells
and in cells in tumoral stroma including endothelial cells
(Takahashi et al, 1990; Zagzag et al, 1990).
In normal breast tissue, bFGF is localized in the myoepithelial
cells, whereas epithelial cells and stroma are negative (Gomm et
al, 1991). As myoepithelial cells are not present in breast carci-
nomas, tumour tissue generally shows lower expression of bFGF
compared with normal tissue (Luqmani et al, 1992; Anandappa
et al, 1994; Yoshiji et al, 1996). However, a fraction of all carci-
nomas display high bFGF expression in neoplastic cells and/or
stromal cells (Visscher et al, 1995).
bFGF is a potent mitogen for endothelial cells in vitro (Bicknell
and Harris, 1991). In a number of studies, no correlation has been
observed between microvessel density and bFGF content in
neoplasms (Visscher et al, 1995; Toi et al, 1996a; Relfet al, 1997),
suggesting that bFGF may not be an important angiogenic factor
in vivo.
Proteases associated with tumour invasion are commonly
expressed in host-derived stromal cells adjacent to tumour cells.
Some proteases, such as the metalloprotease stromelysin-3, are
only expressed by stromal cells (Basset et al, 1990). bFGF has
been demonstrated to induce synthesis of urokinase-type plas-
minogen activator (uPA) and stromelysin-3 in vitro (Sato and
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Rifkin, 1988; Basset et al, 1990). High levels of uPA and
stromelysin-3 have been associated with aggressive clinical behav-
iour (Duffy et al, 1990; Engel et al, 1994).
The aim ofthe present study was to examine the significance of
immunohistochemical staining of bFGF in human breast carci-
nomas. We asked whether bFGF staining was correlated with the
expression of the stromelysin-3 gene in the tumour stroma
(measured by in situ hybridization) and whether bFGF staining
was correlated with microvessel density.
MATERIALS AND METHODS
Tumour selection
Fifty-four cases of invasive primary breast cancer, registered
between 1982 and 1987, were selected from the Stockholm breast
cancer care programme. Formalin-fixed, paraffin-embedded tissue
blocks were sectioned, stained and graded according to the WHO
international histological classification ofbreast tumours.
Immunohistochemistry
The VEGF polyclonal antibody A 20 was obtained from Santa Cruz
and used at a 1:500 dilution. The bFGF polyclonal antibody 147
(SantaCruz) was used at a 1:1000dilution. Four-micrometre sections
were prepared and deparaffinized. For VEGF (but not bFGF)
staining, slides were microwave treated (800 W, 7 min; 450 W 3 x
5 min). After quenching of endogenous peroxidase activity by
incubation in 0.5% hydrogen peroxide for 20 min, slides were pre-
incubated in 1% bovine serum albumin (BSA)/Tris/phosphate-
buffered saline (PBS) (50 mm Tris, PBS, pH 7.6) for 30 min. The
first antibody (diluted in 1% BSA/Tris-PBS) was then added and
incubation was for 16h at +4°C. After washing 3 x 5 min with
Tris-PBS, a biotinylated anti-rabbit IgG (Vector laboratories) was
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Figure 1 Localization of bFGF (A, C, E) by peroxidase immunostaining and stromelysin-3 mRNA (B, D, F) by in situ hybridization in human breast carcinoma
tumours. Note staining of bFGF in stromal cells but not in tumour cells. A and B, 4x objective; C-F 40x objective. C and D show the most intensively stained
areas of A and B in the 40x objective. E and F are from the same area of a bFGF protein- and stromelysin-3 mRNA-negative tumour. Landmarks have been
added in A and B
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Table 1 Association between stromal bFGF staining and stromelysin-3
mRNA in human breast carcinoma
ST-3 mRNA ST-3 mRNA
< 2500 AU > 2500 AU
< 25% Stromal bFGF staining 15 5
> 25% Stromal bFGF staining 11 23
P< 0.003 (X2 = 10.4).
added. After washing, slides were treated with Vectastain and DAB
solution according to the recommendations of the manufacturer
(Vector laboratories).
Staining was scored by two individuals using a dual microscope.
Scoring was performed with no knowledge ofthe clinical outcome
or other properties of the tumours. Tumours were classified as
positive for bFGF or VEGF if more than 25% ofthe cells/tumoral
stroma was positive.
Microvessel density was determined after staining with an anti-
human factor-VIII antibody (Chemicon, Temecula, CA, USA).
Capillary counts were performed for each tumour within the hot
spots of angiogenesis (microvessels per 200x field of tumour
tissue) (Weidner et al, 1991).
In situ hybridization
In situ hybridization was performed on representative samples of
formalin-fixed, paraffin-embedded tumour tissue as described
previously (Engel et al, 1994). In brief, one 6-,im section from
each tumour was hybridized with a 35S-labelled RNA probe (tran-
scribed from a human ST3 cDNA fragment; a gift from P Basset,
Strasbourg, France). After removal of unhybridized probe, slides
were dipped in Kodak NTB2 emulsion. Slides were developed
after 21 days of exposure, developed and haematoxylin-eosin
stained.
The hybridization signal was quantitated using a digital image
analysis system based on an Axioscope microscope (Carl Zeiss)
equipped with a CCD camera (Cohu) and a customized computer
program.
RESULTS
bFGF staining patterns in breast carcinoma
Fifty-four cases of breast carcinomas were examined. The mean
age ofthe patients was 67.7 years, 33% were node positive and the
mean tumour size was 23.8 mm. Formalin-fixed sections were
immunostained with antibodies to basic fibroblast growth factor
(bFGF) using the peroxidase technique. In 15 tumours (27.8%),
Table 3 Relationship between VEGF staining and microvessel density
< 75 microvessels >75 microvessels
per field per field
Negative epithelial VEGF staining 23 (69.7) 10 (30.3)
Positive epithelial VEGF staining 10 (58.8) 7 (41.2)
P < 0.45 (X2 = 0.58). Numbers in parentheses are percentages.
bFGF immunoreactivity was observed in neoplastic cells. bFGF
immunoreactivity in the tumoural stroma was observed in 34 cases
(62.9%). No inter-relationship between tumours that express bFGF
in tumour cells and in stromal cells was observed (X2 = 0.123,
P = 0.73). An example of a tumour showing strong staining in the
stroma but no staining of tumour cells is shown in Figure IC.
Stromal cell staining was observed at the tumour-host interface
and was localized to spindle-shaped, fibroblastic cells. In sections
in which benign tissue was present, immunostaining ofcells in the
basal layer ofducts was observed.
The mean follow-up for this material was 106 months. Overall
survival in the group of patients with tumours that did not show
stromal bFGF staining was 45% (9 out of 20), whereas overall
survival in the group of patients with bFGF-positive tumours was
32% (11 out of34) (Figure 2). This difference was not statistically
significant (%2 = 0.86, P = 0.35).
Correlation between bFGF stromal staining and
stromelysin-3 mRNA expression
Stromelysin-3 (ST-3; MMP-l 1) is expressed in stromal cells adja-
cent to tumour cells in > 95% of all breast cancers (Wolf et al,
1993). ST-3 mRNA expression has previously been determined in
this material by in situ hybridization and image analysis (Engel et
al, 1994). Examples ofthe in situ hybridization pattern is shown in
Figure lB and D. A strong correlation was observed between
bFGF stromal immunostaining and stromal expression of ST-3
mRNA (Table 1). Of 20 tumours that did not show stromal bFGF
staining, strong ST-3 mRNA expression (> 2500 units) was only
observed in five cases (25%). In contrast, 23 of 34 tumours that
showed positive bFGF stromal staining were strongly positive for
ST-3 mRNA (67.6%). This association was significant at the level
of P < 0.003 (X2 = 10.4). The mean recorded ST-3 mRNA signal
was 3757 units in bFGF-positive tumours, compared with 2409 in
bFGF-negative tumours (P < 0.05; Student's t-test) (Table 2).
Although difficult to quantify, we noticed that stromal bFGF
staining and ST3 mRNA expression often appeared to be localized
to the same areas in the tumours. Examples of spatial co-distribu-
tion ofbFGF staining and ST-3 expression are shown in Figure 1.
Table 2 Relationship between stromal bFGF staining and clinicopathological parameters
Mean age (years) Tumour size (mm) ER negative (%) IMD > 758 (%) ST-3 mRNAb
bFGF negative 63.3 ± 10.8 22.4 ± 2.9 33 50 (10 out of 20) 2409 ± 1881
bFGF positive 70.4 ± 10.6 24.6 ± 2.2 47 25 (8 out of 32) 3757 ± 2347
alntratumoral microvessel density (>75 factorVIII staining vessels per microscope field). bStromelysin-3 mRNA expression in 'hot spots' determined by image
analysis.
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Figure 2 Kaplan-Meier plot of survival of patients with tumours that stained
positive ornegative for stromal bFGF
No correlation was observed between bFGF staining in tumour
cells and ST-3 expression in stromal cells. In fact, there was a
weak association between negative epithelial bFGF staining and
ST-3 expression (P < 0.1).
bFGF staining does not correlate to microvessel
density
The intratumoural microvessel density (IMD) for each tumour was
determined after staining for FVIII antigen. Using XI analysis, no
correlation was found between high IMD (>75 capillaries per
microscope field) and positive bFGF staining of tumour cells or
stromal cells (Table 2). No relationship between bFGF staining
and age, tumour size or oestrogen receptor content was observed
(Table 2).
Staining of vascular endothelial growth factor (VEGF)
The finding that bFGF staining did not correlate to microvessel
density prompted us to examine the levels of VEGF in our
material. Nineteen of52 tumours showed strong VEGF staining in
neoplastic cells (36.5%). VEGF staining was not observed to
correlate with IMD (Table 3) nor to reflect disease outcome.
DISCUSSION
Elevated expression of bFGF has been associated with aggressive
clinical behaviour of breast cancer (Visscher et al, 1995), lung
cancer (Takanami et al, 1996) and pancreas cancer (Yamanaka et
al, 1993). In the relatively small amount of material studied here,
there was a trend for more aggressive behaviour of tumours with
positive stromal bFGF staining.
T'he co-localization of bFGF and ST-3 in many tumours and the
relationship between tumours that strongly express bFGF and ST-3
suggest a functional relationship in breast cancer. bFGF has been
demonstrated to induce the expression of ST-3 in human fibroblasts
in vitro (Basset et al, 1990), providing support for such a relation-
ship. The association was limited to stromal bFGF staining and ST-
3 expression, whereas tumour cell bFGF staining was not associated
with ST-3 expression. Therefore, we do not have evidence for a
simple model in which tumour cells induce ST-3 synthesis in
stromal cells via bFGF. The presence of bFGF in host-derived
stromal cells could be interpreted as induction of an autocrine loop,
which may lead to induction of ST-3 expression. Autocrine mecha-
nisms through which endothelial cells are stimulated by tumour
cells to induce bFGF, which in turn induces angiogenesis via an
autocrine loop, have been postulated (Peverali et al, 1994; Bussolino
etal, 1996).
Similar to our findings, Visscher et al (1995) reported that bFGF
immunostaining of stromal cells in breast carcinomas correlates
with the staining of urokinase plasminogen activator (uPA) in
stromal cells. In that study, a significant association between
stromal bFGF staining and disease recurrence was reported. We
conclude, then, that stromal bFGF staining correlates with the
stromal expression of at least two proteases in breast cancer.
The finding of strong bFGF immunoreactivity in host-derived
stromal cells in this and previous studies raises the question of the
origin ofbFGF synthesis. The lack of association between staining
of neoplastic cells and tumoral stroma does not support the idea
that bFGF is synthesized in tumour cells and then accumulated in
fibroblasts. This question should be further examined using in situ
hybridization.
Tumour invasion and angiogenesis are to some extent related
processes that are characterized by matrix proteolysis and cell
migration (Liotta et al, 1991). A number of studies have suggested
that the ability of specific factors to induce angiogenic responses
correlates with their stimulation of matrix protease synthesis in
endothelial cells (Gross et al, 1982; Montesano and Orci, 1985).
For example, antibodies to interstitial collagenase inhibit
endothelial cell invasion (Montesano and Orci, 1985), and metal-
loprotease inhibitors, such as TIMP, inhibit the angiogenic process
(Johnson et al, 1994). We have previously shown that microvessel
density and ST3 expression do not correlate in breast cancer
(Linder et al, 1997), suggesting that the mechanisms that induce
ST3 expression are distinct from those that induce angiogenesis.
In the present study, we did not observe any correlation between
bFGF and microvessel density. Furthermore, we did not find an
association between VEGF and microvessel density or disease
outcome. Previous studies have shown that breast tumours express
multiple growth factors. VEGF is believed to be one of the most
important ofthe angiogenic factors described so far, and it is highly
expressed in breast cancer (Brown et al, 1995; Toi et al, 1996b;
Relfet al, 1997). In some studies, VEGF expression has been asso-
ciated with poor prognosis in breast cancer (Toi et al, 1996b; Relf
et al, 1997) and gastric cancer (Maeda et al, 1996). Whereas Toi et
al (1994) found that VEGF-rich tumours have a higher microvessel
density, Relf et al (1997) did not report any such association.
Considering the number of different angiogenic factors expressed
in breast cancer (Relfet al, 1997), a strong association between one
factor and angiogenesis might not be expected.
The stromelysin-3 gene is a paradigm for protease genes
expressed in tumoral stroma. The correlation between stromelysin-
3 expression and stromal bFGF staining has not been reported
previously. This finding suggests a functional relationship and
raises the possibility that blocking of the activity of bFGF may
represent one approach to therapy.
ACKNOWLEDGEMENTS
We are grateful to Inga Maurin for technical assistance. This work
was supported by the Welcome Foundation, Gustav Vs Jubilee
Foundation and by Cancerforeningen i Stockholm.
British Journal ofCancer (1998) 77(6), 941-945 0 CancerResearch Campaign 1998Basic fibroblast growth factorimmunostaining in breast carcinoma 945
REFERENCES
Anandappa SY, Winstanley JH, Leinster S, Green B, Rudland P and Barraclough R
(1994) Comparative expression of fibroblast growth factor mRNAs in benign
and malignant breast disease. BrJ Cancer 69: 772-776
Basilico C and Moscatelli D (1992) The FGF family ofgrowth factors and
oncogenes. Adv CancerRes 59: 115-165
Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard
MP, Rio MC and Chambon P (1990) A novel metalloproteinase gene
specifically expressed in stromal cells of breast carcinomas. Nature 348:
699-704
Bicknell R, and Harris AL (1991) Novel growth regulatory factors and tumour
angiogenesis. Eur J Cancer 27: 781-785
Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR,
Connolly JL, and Schnitt SJ (1995) Expression of vascular permeability factor
(vascular endothelial growth factor) and its receptors in breast cancer. Hum
Pathol 26: 86-91
Bussolino F, Albini A, Camussi G, Presta M, Viglietto G, Ziche M and Persico G
(1996) Role of soluble mediators in angiogenesis. EurJ Cancer 32A:
2401-2412.
Duffy MJ, Reilly D, O'Sullivan CNOH, Fennelly JJ and Andreasen P (1990)
Urokinase-plasminogen activator, a new and independent prognostic marker in
breast cancer. Cancer Res 50: 6827-6829
Engel G, Heselmeyer K, Auer G, Backdahl M, Eriksson E and Linder S (1994)
Correlation between stromelysin-3 mRNA level and outcome ofhuman breast
cancer. IntJ Cancer 58: 830-835
Folkman J and Shing Y (1992) Angiogenesis. JBiol Chem 267: 10931-10933
Gomm JJ, Smith J, Ryall GK, Baillie R, Tumbull L and Coombes RC (1991)
Localization ofbasic fibroblast growth factor and transforming growth factor
beta 1 in the human mammary gland. Cancer Res 51: 4685-4692
Gross JL, Moscatelli D, Jaffe EA and Rifkin DB (1982) Plasminogen activator and
collagenase production by cultured capillary endothelial cells. J Cell Biol 95:
974-981
Johnson MD, Kim H-RC, Chesler L, Tsao-Wu G, Bouck N and Polverini PJ (1994)
Inhibition of angiogenesis by tissue inhibitor ofmetalloproteinase. J Cell Phys
160: 194-202
Linder C, Engel G, Auer G, Strander H and Linder S (1997) Distribution of
stromelysin-3 mRNA transcripts and microvessels in human breast carcinomas.
Breast Cancer Res Treat 42: 207-213
Liotta LA, Steeg PS and Stetler-Stevenson WG (1991) Cancer metastasis and
angiogenesis: an imbalance ofpositive and negative regulation. Cell 64:
327-336
Luqmani YA, Graham M and Coombes RC (1992) Expression ofbasic fibroblast
growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and
comparison with other normal tissues. BrJ Cancer 66: 273-280
Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T and
Sowa M (1996) Prognostic value of vascular endothelial growth factor
expression in gastric carcinoma. Cancer 77: 858-863
Montesano R and Orci L (1985) Tumor-promoting phorbol esters induce
angiogenesis in vitro. Cell 42: 469-477
Peverali FA, Mandriota SJ, Ciana P, Marelli R, Quax P, Rifkin DB, Della Valle G
and Mignatti P (1994) Tumor cells secrete an angiogenic factor that stimulates
basic fibroblast growth factor and urokinase expression in vascular endothelial
cells. J Cell Physiol 161: 1-14
Relf M, LeJeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse
R, Bicknell R and Harris AL (1997) Expression ofthe angiogenic factors
vascular endothelial growth factor, acidic and basic fibroblast growth factor,
tumor growth factor ,-1, platelet-derived endothelial cell growth factor,
placenta growth factor, and pleiotropin in human primary breast cancer and its
relation to angiogenesis. Cancer Res 57: 963-969
Sato Y and Rifkin DB (1988) Autocrine activities ofbasic fibroblast growth factor:
regulation ofendothelial cell movement, plasminogen activator synthesis, and
DNA synthesis. J Cell Biol 107: 1199-1205
Takahashi JA, Mori H, Fukumoto M, Igarashi K, Jaye MYO, Kikuchi H and M., H
(1990) Gene expression offibroblast growth factors in human gliomas and
meningiomas: demonstration ofcellular source ofbasic fibroblast growth factor
mRNA and peptide in tumour tissues. Proc NatlAcad Sci USA 87: 5710-5714
Takanami I, Imamura T, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and
Kodaira S (1996) Immunohistochemical detection ofbasic fibroblast growth
factor as a prognostic indicator in pulmonary adenocarcinoma. Jpn J Clin
Oncol 26: 293-297
Toi M, Hoshina S, Takayanagi T and Tominaga T (1994) Association of vascular
endothelial growth factor expression with tumour angiogenesis and with early
relapse in primary breast cancer. Jpn J Cancer Res 85: 1045-1049
Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T and
Tominaga T (1996a) Quantitative analysis ofvascular endothelial growth factor
in primary breast cancer. Cancer 77: 1101-1106
Toi M, Tanaguchi T, Yamamoto Y, Kurisaki T, Suzuki H and Tominaga T (1996b)
Clinical significance ofthe determination ofangiogenic factors. EurJ Cancer
32A: 2513-2519.
Visscher DW, DeMattia F, Ottosen S, Sarkar FH and Crissman JD (1995) Biologic
and clinical significance ofbasic fibroblast growth factor immunostaining in
breast carcinoma. Modern Pathol 8: 665-670
Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumour angiogenesis and
metastasis - correlation in invasive breast carcinoma. N Engl JMed 324: 1-8
WolfC, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq J-P, Chambon P and Basset P
(1993) Stromelysin 3 belongs to a subgroup ofproteinases expressed in breast
carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc
NatlAcad Sci USA 90: 1843-1847
Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, Kobrin MS and
Korc M (1993) Overexpression of acidic and basic fibroblast growth factors in
human pancreatic cancer correlates with advanced tumor stage. Cancer Res 53:
5289-5296
Yoshiji H, Gomez DE, Shibuya M and Thorgeirsson UP (1996) Expression of
vascular endothelial growth factor, its receptor, and other angiogenic factors in
human breast cancer. Cancer Res 56: 2013-2016
Zagzag D, Miller DC, Sato Y, Rifkin DB and Burstein DE (1990) Immunohisto-
chemical localization ofbasic fibroblast growth factor in astrocytomas. Cancer
Res 50: 7393-7398
C Cancer Research Campaign 1998 British Journal of Cancer (1998) 77(6), 941-945